NO20061600L - Bensotiazol-derivater for behandling av diabetes - Google Patents

Bensotiazol-derivater for behandling av diabetes

Info

Publication number
NO20061600L
NO20061600L NO20061600A NO20061600A NO20061600L NO 20061600 L NO20061600 L NO 20061600L NO 20061600 A NO20061600 A NO 20061600A NO 20061600 A NO20061600 A NO 20061600A NO 20061600 L NO20061600 L NO 20061600L
Authority
NO
Norway
Prior art keywords
unsubstituted
substituted
treatment
benzothiazole derivatives
group
Prior art date
Application number
NO20061600A
Other languages
English (en)
Norwegian (no)
Inventor
Jean-Pierre Gotteland
Pascale Gaillard
Pierre-Alain Vitte
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20061600L publication Critical patent/NO20061600L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20061600A 2003-09-12 2006-04-07 Bensotiazol-derivater for behandling av diabetes NO20061600L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102740 2003-09-12
PCT/EP2004/052090 WO2005025567A1 (en) 2003-09-12 2004-09-08 Benzothiazole derivatives for the treatment of diabetes

Publications (1)

Publication Number Publication Date
NO20061600L true NO20061600L (no) 2006-04-07

Family

ID=34306921

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061600A NO20061600L (no) 2003-09-12 2006-04-07 Bensotiazol-derivater for behandling av diabetes

Country Status (17)

Country Link
US (2) US20070088017A1 (de)
EP (1) EP1696909B1 (de)
JP (1) JP5021307B2 (de)
AT (1) ATE378047T1 (de)
AU (1) AU2004271740B2 (de)
CA (1) CA2534314C (de)
CY (1) CY1107820T1 (de)
DE (1) DE602004010178T2 (de)
DK (1) DK1696909T3 (de)
ES (1) ES2297494T3 (de)
HR (1) HRP20070527T3 (de)
IL (1) IL174250A (de)
NO (1) NO20061600L (de)
PL (1) PL1696909T3 (de)
PT (1) PT1696909E (de)
SI (1) SI1696909T1 (de)
WO (1) WO2005025567A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838522B2 (en) * 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
EP1942879A1 (de) 2005-10-31 2008-07-16 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
DK2054049T3 (en) 2006-08-24 2016-08-01 Univ Tennessee Res Found SUBSTITUTED ACYLANILIDES AND PROCEDURES FOR USING THEREOF
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008125518A2 (en) * 2007-04-17 2008-10-23 Merck Serono S.A. Process for the preparation of piperazine benzothiazoles
UA100527C2 (en) * 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
PL2872482T3 (pl) 2012-07-13 2021-03-08 Oncternal Therapeutics, Inc. Sposób leczenia raków sutka z użyciem selektywnego modulatora receptora androgenowego (sarm)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
CN104903331A (zh) * 2013-01-24 2015-09-09 山东亨利医药科技有限责任公司 Jnk抑制剂
WO2017025980A2 (en) * 2015-08-12 2017-02-16 Shoolineuniversity Of Biotechnology And Management Sciences Novel benzothiazole derivatives with enhanced biological activity
CN115887434B (zh) * 2022-11-23 2024-12-24 四川大学 具有抗氧化作用的药物用于制备治疗多囊卵巢综合征药物的用途
US11970467B1 (en) 2023-10-13 2024-04-30 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound
US11905260B1 (en) 2023-10-13 2024-02-20 King Faisal University N′-(1-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1176269A (en) * 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
EP1110957A1 (de) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazolderivate und ihre Verwendung als JNK Modulatoren
EP1450792B1 (de) * 2001-12-07 2006-09-27 Applied Research Systems ARS Holding N.V. Benzazole derivate zur behandlung von scleroderma
RS51407B (sr) * 2002-04-25 2011-02-28 Laboratoires Serono Sa Piperazinski benzotijazoli kao agensi za lečenje cerabralnih ishemičnih poremećaja ili poremećaja cns

Also Published As

Publication number Publication date
SI1696909T1 (sl) 2008-02-29
DE602004010178T2 (de) 2008-09-11
WO2005025567A1 (en) 2005-03-24
PT1696909E (pt) 2007-12-21
DE602004010178D1 (de) 2007-12-27
AU2004271740A1 (en) 2005-03-24
ATE378047T1 (de) 2007-11-15
EP1696909A1 (de) 2006-09-06
CA2534314C (en) 2012-11-13
DK1696909T3 (da) 2008-01-02
CY1107820T1 (el) 2013-06-19
HK1096594A1 (en) 2007-06-08
HRP20070527T3 (en) 2007-12-31
AU2004271740B2 (en) 2010-10-28
ES2297494T3 (es) 2008-05-01
EP1696909B1 (de) 2007-11-14
US20070088017A1 (en) 2007-04-19
JP2007505083A (ja) 2007-03-08
PL1696909T3 (pl) 2008-04-30
IL174250A (en) 2011-01-31
CA2534314A1 (en) 2005-03-24
JP5021307B2 (ja) 2012-09-05
US20140107116A1 (en) 2014-04-17
IL174250A0 (en) 2006-08-01

Similar Documents

Publication Publication Date Title
CY1107820T1 (el) Παραγωγα βενζοθειαζολιου για την θεραπευτικη αντιμετωπιση του διαβητη
ATE557030T1 (de) Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
NO20083026L (no) Terapeutisk middel for diabetes
NO20080728L (no) Nye 1,4-benzotiazepin-1,1-dioksidderivater som har forbedrede egenskaper, fremgangsmate for fremstilling derav, medikamenter inneholdende nevnte forbindelsene og anvendelse derav
DE60325740D1 (de) Verwendung von protein-kinase-n-beta
WO2010045303A3 (en) Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
PA8566201A1 (es) Nuevos derivados de piridina y quinolina
NO20063431L (no) 3-(4-Benzyloksyfenyl)propionsyrederivater
SE0102299D0 (sv) Compounds
CY1112466T1 (el) ΠΥΡΡΟΛΙΔΙΝΟΝΕΣ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΜΕ ΠΙΠΕΡΙΔΙΝΥΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ 11-β-ΥΔΡΟΞΥΣΤΕΡΟΕΙΔΟΥΣ ΑΦΥΔΡΟΓΟΝΑΣΗΣ 1
NO20060870L (no) Fluorsubstituert omega-karboksyaryldifenylurea for behandling og profylakse av sykdommer og tilstander
CL2007003261A1 (es) Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, tales como esquizofrenia,
NO20054713L (no) C-glycosidderivater og salter derav
NO20061153L (no) Trans-1-(6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
CY1107398T1 (el) Νεα διφαινυλαζητιδoνη με βελτιωμενες φυσιολογικες ιδιοτητες, η διαδικασια για την παραγωγη της, το φαρμακευτικο παρασκευασμα που περιεχει τις ενωσεις αυτες καθως και η χρηση του
ATE455772T1 (de) Alkinylarylcarbonsäureamide
NO20061614L (no) Benzimidazolacetonitriler
BRPI0519329A2 (pt) Ácidos hidroxibifenil carboxÍlicos e derivados, mÉtodos para produÇço dos mesmos e uso dos mesmos
BRPI0911497B8 (pt) derivados de nip tiazol, seu processo de fabricação, medicamento, composição farmacêutica, e kit
NO20061599L (no) Benzoksazol acetonitriler
MA28339A1 (fr) Derives de l'acide 7- amino-4-quinolone-3-carboxylique substitues de maniere heterocyclique, methode pour leur production et leur utilisation en tant que medicaments
DK1656139T3 (da) Aryldicarboxamider
TWI256952B (en) Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application